Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Ascending Dose Study of ITI-9001 in Japanese Red Cedar Pollinosis
jRCT2033260217Phase 1Recruiting
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Jun 2026
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ITI-9001 in Japanese cedar pollinosis (4 arms), sponsored by Immunomic Therapeutics, Inc. Primary endpoints: Dose-limiting toxicities in Part A, Treatment-emergent adverse events and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
ITI-9001
03
Conditions
Japanese cedar pollinosis
Beyond the preview
Go deeper on jRCT2033260217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033260217.